OncLiveDr. Sampath on Immunotherapy and Radiation Combinations in NSCLCOncLiveSagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses combinations of immunotherapy and radiation for the treatment of patients wi… Continue reading
Stanford Medical Center Report |
New technique could reveal immunotherapy targets
Stanford Medical Center Report What’s more, the technique could serve to identify potential antigens relevant to other immunotherapies, such as those that combat autoimmune or infectious diseases. A paper describing the work was published online Dec. 21 in Cell. Stanford graduate … |
Stanford Medical Center Report |
New technique could reveal immunotherapy targets
Stanford Medical Center Report What’s more, the technique could serve to identify potential antigens relevant to other immunotherapies, such as those that combat autoimmune or infectious diseases. A paper describing the work was published online Dec. 21 in Cell. Stanford graduate … |
FiercePharma |
Juno Therapeutics, Thermo Fisher ink partnership deal to manufacture CAR–T therapies
FiercePharma The beads activate and expand T cells that have been genetically engineered to recognize and fight cancer cells in each individual patient. Financial terms of the deal weren’t disclosed. CAR-T drugs are made of a patient’s own cells that are removed … Thermo Fisher Scientific agrees manufacturing deal with Juno TherapeuticsZenopa |
The Lincolnian Online |
Crispr Therapeutics (CRSP) Rating Reiterated by Oppenheimer
The Lincolnian Online Crispr Therapeutics (NASDAQ:CRSP)’s stock had its “hold” rating reiterated by Oppenheimer in a report issued on Thursday. A number of other brokerages also recently weighed in on CRSP. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a … Cann Reaffirms “Hold” Rating for Crispr Therapeutics (NASDAQ …StockNewsTimes Crispr Therapeutics AG (CRSP) Insider Tyler Dylan-Hyde Sells …Dispatch Tribunal |